Literature DB >> 10950949

Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7.

I Sher1, T Lang, S Lubinsky-Mink, J Kuhn, N Adir, S Chatterjee, D Schomburg, D Ron.   

Abstract

Fibroblast growth factors (FGFs) mediate a multitude of physiological and pathological processes by activating a family of tyrosine kinase receptors (FGFRs). Each FGFR binds to a unique subset of FGFs and ligand binding specificity is essential in regulating FGF activity. FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR. Previously, mutations in FGF-2 identified a set of residues that are important for high affinity receptor binding, known as the primary receptor-binding site. FGF-7 contains this primary site as well as a region that restricts interaction with FGFR1. The sequences that confer on FGF-7 its specific binding to KGFR have not been identified. By utilizing domain swapping and site-directed mutagenesis we have found that the loop connecting the beta4-beta5 strands of FGF-7 contributes to high affinity receptor binding and is critical for KGFR recognition. Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1. Point mutations in residues comprising this loop of FGF-7 reduced both binding affinity and biological potency. The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR. Our results show that topologically similar regions in these two FGFs have different roles in regulating receptor binding specificity and suggest that specificity may require the concerted action of distinct regions of an FGF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10950949     DOI: 10.1074/jbc.M003293200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Sustained activation of the HER1-ERK1/2-RSK signaling pathway controls myoepithelial cell fate in human mammary tissue.

Authors:  Lejla Pasic; T S Karin Eisinger-Mathason; Bisi T Velayudhan; Christopher A Moskaluk; David R Brenin; Ian G Macara; Deborah A Lannigan
Journal:  Genes Dev       Date:  2011-08-01       Impact factor: 11.361

2.  Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors.

Authors:  Brian K Yeh; Makoto Igarashi; Anna V Eliseenkova; Alexander N Plotnikov; Ifat Sher; Dina Ron; Stuart A Aaronson; Moosa Mohammadi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-18       Impact factor: 11.205

3.  Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents.

Authors:  Mohamed Izikki; Christophe Guignabert; Elie Fadel; Marc Humbert; Ly Tu; Patricia Zadigue; Philippe Dartevelle; Gerald Simonneau; Serge Adnot; Bernard Maitre; Bernadette Raffestin; Saadia Eddahibi
Journal:  J Clin Invest       Date:  2009-02-09       Impact factor: 14.808

4.  BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1.

Authors:  Johannes Grimm; Anita Hufnagel; Marion Wobser; Andreas Borst; Sebastian Haferkamp; Roland Houben; Svenja Meierjohann
Journal:  Oncogenesis       Date:  2018-09-20       Impact factor: 7.485

5.  Stilbene glycosides are natural product inhibitors of FGF-2-induced angiogenesis.

Authors:  Sajjad Hussain; Mark Slevin; Nessar Ahmed; David West; Muhammad Iqbal Choudhary; Humera Naz; John Gaffney
Journal:  BMC Cell Biol       Date:  2009-04-23       Impact factor: 4.241

6.  Cheiradone: a vascular endothelial cell growth factor receptor antagonist.

Authors:  Sajjad Hussain; Mark Slevin; Mohammad A Mesaik; Mohammad I Choudhary; Abdul H Elosta; Sabine Matou; Nessar Ahmed; David West; John Gaffney
Journal:  BMC Cell Biol       Date:  2008-01-29       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.